




RealRate

PHARMACEUTICAL 2023

Dianthus Therapeutics Inc DE
Rank 211 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Dianthus Therapeutics Inc DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dianthus Therapeutics Inc DE compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 59% points. The greatest weakness of Dianthus Therapeutics Inc DE is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 38% points.

The company's Economic Capital Ratio, given in the ranking table, is 278%, being 34% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	115,602
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,549
Liabilities, Non-Current	26,138
Other Assets	24,948
Other Compr. Net Income	-151
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	4,440
Property and Equipment	6,095
Research and Development	55,141
Selling, General and Administrative Expense	25,761

Output Variable	Value in 1000 USD
Assets	146,645
Liabilities	40,687
Expenses	80,902
Revenues	4,440
Stockholders Equity	105,958
Net Income	-76,462
Comprehensive Net Income	-76,538
BaseVar	136,412
ECR before LimitedLiability	165%
Economic Capital Ratio	278%